Trial intelligence / Profile preview

Levomilnacipran ER for Fatigue in MDD

NCT01254305Phase 2Completed

Sponsor
Forest Laboratories
Start
Apr 2011
Primary completion
Jul 2012
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of levomilnacipran in major depressive disorder (MDD), sponsored by Forest Laboratories. Started Apr 2011; status: completed.

02

Drugs

levomilnacipran
03

Conditions

major depressive disorder (MDD)

Beyond the preview

Go deeper on NCT01254305.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01254305.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call